Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY‐1816, in pancreatic ductal adenocarcinoma

Despite tremendous efforts, the clinical prognosis of pancreatic ductal adenocarcinoma (PDAC) remains disappointing. There is an urgent need to develop more effective treatment strategies to improve the prognosis of patients with PDAC. In this study, we evaluate the anti‐PDAC effects of LY‐1816, a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wei, Meng, Lingwei, Chen, Kai, Tian, Chenyu, Peng, Bing, Zhong, Lei, Zhang, Chunhui, Yang, Xin, Zou, Jun, Yang, Shengyong, Li, Linli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447837/
https://www.ncbi.nlm.nih.gov/pubmed/30618127
http://dx.doi.org/10.1111/cas.13929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447837/
https://www.ncbi.nlm.nih.gov/pubmed/30618127
http://dx.doi.org/10.1111/cas.13929

Ejemplares similares